youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
MRNA:NASDAQ
Moderna Inc
$220.83
arrow_downward
-0.40%(-0.89) 1D
$220.18
arrow_downward
-0.30% (-0.65)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MRNA...
Open
$224.16
High
$230.52
Low
$217.62
Mkt. cap
88.16B
Avg. vol.
18.56M
Volume
8.44M
52-wk high
$254.48
52-wk low
$22.29
EPS
-$7.98
Beta
1.09
Shares outstanding
399.24M
No. of employees
5K
Open
$224.16
High
$230.52
Low
$217.62
Mkt. cap
88.16B
Avg. vol.
18.56M
Volume
8.44M
52-wk high
$254.48
52-wk low
$22.29
EPS
-$7.98
Beta
1.09
Shares outstanding
399.24M
No. of employees
5K
News stories
From web sources and news partners
BioSpace
·
58 minutes ago
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
Zacks
·
10 hours ago
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
Zacks
·
10 hours ago
Buy Moderna Stock Before Q3 Earnings? Here's What to Know
Zacks Investment Research
·
11 hours ago
Buy Moderna Stock Before Q3 Earnings? Here's What to Know
Profile
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
About Moderna Inc
Analyst ratings
Based on 20 analysts giving stock ratings to MRNA in the past 3 months
Hold
Buy
2
Hold
15
Sell
3
12-month forecast
Based on 20 Wall Street analysts offering 12 month price targets for MRNA in the last 3 months.
Highest
Current $220.83
$230.00 (+4.15%)
Average
$127.69 (-42.18%)
Lowest
$45.00 (-79.62%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Luca Issi RBC Capital | Hold | Maintained | $130.00 | -41.1% | 10/27/2026 |
Myles Minter William Blair | Hold | Downgraded | - | - | 10/27/2026 |
Geoff Meacham Citi | Sell | Maintained | $80.00 | -63.8% | 10/27/2026 |
Cory Kasimov Evercore ISI | Hold | Maintained | $80.00 | -63.8% | 10/26/2026 |
Courtney Breen Bernstein | Hold | Maintained | $45.00 | -79.6% | 10/25/2026 |
Alec Stranahan Bank of America Securities | Hold | Maintained | $220.00 | -0.4% | 10/27/2026 |
Eliana Merle Barclays | Hold | Maintained | $125.00 | -43.4% | 10/26/2026 |
Edward Tenthoff Piper Sandler | Buy | Reiterated | $230.00 | +4.2% | 10/26/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $137.00 | -38% | 10/25/2026 |
Tyler Van Buren TD Cowen | Hold | Maintained | $90.00 | -59.2% | 10/21/2026 |
Terence Flynn Morgan Stanley | Hold | Reiterated | $95.00 | -57% | 10/07/2026 |
Jessica Fye J.P. Morgan | Sell | Maintained | - | - | 09/28/2026 |
Andrew Tsai Jefferies | Hold | Maintained | $150.00 | -32.1% | 09/22/2026 |
Nico Chen DBS | Hold | Maintained | $150.00 | -32.1% | 09/11/2026 |
Harry Gillis Berenberg Bank | Hold | Maintained | $100.00 | -54.7% | 09/10/2026 |
Simon Baker CFA Rothschild & Co Redburn | Sell | Downgraded | $81.00 | -63.3% | 09/03/2026 |
Jasper Hellweg Argus Research | Buy | Upgraded | $180.00 | -18.5% | 08/27/2026 |
Alexandria Hammond Wolfe Research | Hold | Upgraded | - | - | 08/25/2026 |
Michael Yee UBS | Hold | Maintained | $150.00 | -32.1% | 08/20/2026 |
Joseph Stringer Needham | Hold | Maintained | - | - | 08/19/2026 |
Unknown Analyst Berenberg Bank | Hold | Maintained | $45.00 | -79.6% | 07/31/2026 |
Unknown Analyst J.P. Morgan | Sell | Maintained | $40.00 | -81.9% | 05/20/2026 |
Mani Foroohar Leerink Partners | Sell | Maintained | $12.00 | -94.6% | 02/11/2026 |
Next call in 3 days
Fri, Nov 6, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$1.35
Revenue / Est. (USD)
- / 890.22M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.02B | 678.00M | 389.00M | 145.00M |
Cost of goods sold | 1.01B | 1.23B | 726.00M | 738.00M |
Cost of revenue | 1.01B | 1.23B | 726.00M | 738.00M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 268.00M | 308.00M | 173.00M | 216.00M |
Operating expense | 268.00M | 308.00M | 173.00M | 216.00M |
Total operating expenses | 1.28B | 1.54B | 899.00M | 954.00M |
Operating income | -260.00M | -857.00M | -510.00M | -809.00M |
Other non operating income | -4.00M | -2.00M | - | -2.00M |
EBT including unusual items | -187.00M | -799.00M | -1.33B | -767.00M |
EBT excluding unusual items | -191.00M | -797.00M | -455.00M | -761.00M |
Income tax expense | 13.00M | 27.00M | 9.00M | 15.00M |
Effective tax rate | -6.95% | -3.38% | -0.67% | -1.96% |
Other operating expenses | - | - | - | - |
Net income | -200.00M | -826.00M | -1.34B | -782.00M |
Net profit margin | -19.68% | -121.83% | -345.24% | -539.31% |
Earnings per share | -0.51 | -2.11 | -3.40 | -1.97 |
Interest and investment income | 73.00M | 70.00M | 72.00M | 67.00M |
Interest expense | - | -8.00M | -17.00M | -17.00M |
Net interest expenses | 73.00M | 62.00M | 55.00M | 50.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -208.00M | -790.00M | -451.00M | -746.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events